The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Mylotarg (gemtuzumab ozogamicin) granted approval in the EU for use in previously untreated, de novo, CD33-positive AML
On 23rd April 2018, the European Commission (EC) granted approval to Mylotarg (gemtuzumab ozogamicin), an antibody drug conjugate (ADC), in combination with daunorubicin and cytarabine for the treatment of patients aged 15 years and above with previously untreated, de novo, CD33-positive acute myeloid leukemia (AML).1 This approval comes after the ‘positive opinion’ recommendation of Mylotarg by the European Medicines Agency(EMA) Committee for Medicinal Products for Human Use (CHMP) in February 2018 and the U.S. Food and Drug Administration (FDA) approval in September 2017.
The approval by the EC for Mylotarg was based on results obtained from the phase III ALFA-701 study (NCT00927498). Data from the ALFA-701 study showed that combination of Mylotarg with standard chemotherapy regimen in newly diagnosed de novo AML patients significantly improved 3-year Event Free Survival (EFS) and Relapse Free Survival (RFS) compared to chemotherapy alone.2
Mylotarg’s manufacturers, Pfizer, noted that Mylotarg “is the first and only AML therapy approved in the European Union (EU) that targets CD33, an antigen expressed on AML cells in up to 90% of patients”.1
References